Jinssico Signs MOU with Theragen Genome Care to Provide Cancer Risk Assessment Service for Health Checkups

GeneCker, a company developing a genome testing platform using CRISPR gene editing technology (CEO Yesunghyuk), signed a business agreement (MOU) with NGS analysis service company Theragen Genome Care (CEO Im Honggye) on the 16th.

GeneCker is a diagnostic kit development company aiming to standardize liquid biopsy cancer diagnosis based on ultra-precise gene analysis technology. By developing the world's first cancer diagnostic kit incorporating ultra-precise gene editing (CRISPR), it overcame the sensitivity limitations of existing cancer diagnostic genetic tests, enabling precise cancer gene diagnosis using only blood.

Theragen Genome Care is a leading prenatal genetic analysis company providing cutting-edge testing services by integrating world-class genome decoding capabilities and bioinformatics technology. Through this agreement, it will provide services including management of liquid biopsy specimens for screening, production and quality control of NGS data, and data analysis for cancer risk screening tests.

Through this agreement, both companies will develop an NGS panel for health checkups using liquid biopsy and establish a scoring system to predict disease risk, providing information for monitoring the health status of examinees and future health management.

Yesunghyuk, CEO of GeneCker, stated, “Through this agreement, we expect to improve the efficiency of personal health management by providing NGS services for health checkups based on liquid biopsy.”

Im Honggye, CEO of Theragen Genome Care, commented, “We will collaborate to develop and enhance the performance of health checkup services based on our extensive experience and knowledge accumulated through liquid biopsy testing. Additionally, we will make this agreement an opportunity to contribute to the improvement of national health management.”